|
1）Matveyenko AV, et al. Relationship between β-cell mass and diabetes onset. Diabetes Obes Metab. 2008; 10: 23-31
|
|
|
|
2）Matsumoto S, et al. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet. 2005; 365: 1642-4
|
|
|
|
|
|
3）Yamada Y, et al. SUIT, secretory units of islets in tansplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes. Diabetes Res Clin Pract. 2006; 74: 222-6
|
|
|
|
|
|
4）Holmberg D, et al. Imaging the pancreas: from ex vivo to non-invasive technology. Diabetologia. 2008; 51: 2148-54
|
|
|
|
|
|
5）Di Gialleonardo V, et al. Imaging of β-cell mass and insulitis in insulin-dependent (Type1) diabetes mellitus. Endocr Rev. 2012; 33: 892-919
|
|
|
|
|
|
6）Lu Y, et al. Bioluminescent monitoring of islet graft survival after transplantation. Mole Ther. 2004; 9: 428-35
|
|
|
|
|
|
7）Harvey CJ, et al. Advances in ultrasound. Clin Radiol. 2002; 57: 157-77
|
|
|
|
|
|
8）Sakata N, et al. Monitoring transplanted islets by high-frequency ultrasound. Islet. 2011; 3: 259-66
|
|
|
|
|
|
9）Arifin RD, et al. Microcapsules with intrinsic barium radiopacity for immunoprotection and X-ray/CT imaging of pancreatic islet cells. Biomaterials. 2012; 33: 4681-89
|
|
|
|
|
|
10）Daniel J, et al. MRI of Transplanted Pancreatic Islets. Magn Reson Med. 2004; 52: 1228-33
|
|
|
|
|
|
11）Medarova Z, et al. MRI as a tool to monitor islet transplantation. Nat Rev Endocrinol. 2009; 5: 444–52
|
|
|
|
|
|
12）Patrick F, et al. Noninvasive assessment of pancreatic β-cell function in vivo with manganese-enhanced magnetic resonance imaging. Am J Physiol Endocrinol Metab. 2009; 296: E573-8
|
|
|
|
|
|
13）Malaisse WJ. On the track to the beta-cell. Diabetologia. 2001; 44: 393-406
|
|
|
|
|
|
14）Sweet IR, et al. Systematic screening of potential β-cell imaging agnets. Biochem Biophys Res Commun. 2004; 314: 976-83
|
|
|
|
|
|
15）Amartey JK, et al. Radioiodinated naphthylalanine derivatives targeting pancratic beta cells in normal and nonobese diabetic mice. Exp Diabetes Res. 2008; 2008: 371716
|
|
|
|
|
|
16）Souza F, et al. Longitudinal noninvasive PET-based β cell mass estimates in a spontaneou diabetes rat model. J Clin Invest. 2006; 116: 1506-13
|
|
|
|
|
|
17）Kim JS, et al. Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival. Nat Med. 2006; 12: 1423-8
|
|
|
|
|
|
18）Normandin DM, et al. In vivo imaging of endo-genous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET. J Nucl Med. 2012; 53: 908-16
|
|
|
|
|
|
19）Mukai E, Toyoda K, Kimura H, et al. GLP-1 receptor antagonist as a potential probe for pancreatic β-cell imaging. Biochem Biophys Res Commun. 2009; 389: 523-6
|
|
|
|
|
|
20）Toyoda K, et al. Non-invasive PET imaging of pancreatic islets targeting glucagon-like peptide-1 receptors. Diabetes. 2010; 59 Supplement(1): A431
|
|
|
|
|
|
21）Wicki A, et al. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma. Clin Cancer Res. 2007; 13: 3696-705
|
|
|
|
|
|
22）Pattou F, et al. GLP-1-Receptor scanning for imaging of human beta cells transplanted in muscle. New Engl J Med. 2010; 363: 13
|
|
|
|
|